OKYO Pharma Limited (OKYO)
1.23
-0.02 (-1.60%)
At close: Apr 03, 2025, 3:59 PM
1.18
-3.78%
After-hours: Apr 03, 2025, 06:02 PM EDT
Company Description
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
Its lead product includes OK-101 for the treatment of dry eye disease.
The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.
OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO Pharma Limited
| Country | GB |
| IPO Date | May 17, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Dr. Gary S. Jacob Ph.D. |
Contact Details
Address: 55 Park Lane London, GB | |
| Website | https://www.okyopharma.com |
Stock Details
| Ticker Symbol | OKYO |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001849296 |
| CUSIP Number | 679345108 |
| ISIN Number | US6793451088 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gary S. Jacob Ph.D. | Chief Executive Officer & Executive Director |
| Keeren Shah | Chief Financial Officer |
| Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer |
| Michael Paul Beck | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | 6-K | Filing |
| Mar 18, 2025 | SCHEDULE 13G | Filing |
| Mar 10, 2025 | 6-K | Filing |
| Feb 12, 2025 | 6-K | Filing |
| Jan 31, 2025 | 6-K | Filing |
| Jan 29, 2025 | 6-K | Filing |
| Jan 22, 2025 | 6-K | Filing |
| Nov 26, 2024 | 6-K | Filing |
| Oct 30, 2024 | 6-K | Filing |
| Oct 23, 2024 | 6-K | Filing |